These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 26047809)

  • 41. Prognostic relevance of activated Akt kinase in node-negative breast cancer: a clinicopathological study of 99 cases.
    Schmitz KJ; Otterbach F; Callies R; Levkau B; Hölscher M; Hoffmann O; Grabellus F; Kimmig R; Schmid KW; Baba HA
    Mod Pathol; 2004 Jan; 17(1):15-21. PubMed ID: 14631376
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Overexpression of phosphoprotein phosphatase 2A predicts worse prognosis in patients with breast cancer: a 15-year follow-up.
    Chen PM; Chu PY; Tung SL; Liu CY; Tsai YF; Lin YS; Wang WL; Wang YL; Lien PJ; Chao TC; Tseng LM
    Hum Pathol; 2017 Aug; 66():93-100. PubMed ID: 28603063
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Correlation and prognostic value of SIRT1 and Notch1 signaling in breast cancer.
    Cao YW; Li WQ; Wan GX; Li YX; Du XM; Li YC; Li F
    J Exp Clin Cancer Res; 2014 Nov; 33(1):97. PubMed ID: 25420528
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Evaluation of vascular endothelial growth factor as a prognostic marker for local relapse in early-stage breast cancer patients treated with breast-conserving therapy.
    Moran MS; Yang Q; Goyal S; Harris L; Chung G; Haffty BG
    Int J Radiat Oncol Biol Phys; 2011 Dec; 81(5):1236-43. PubMed ID: 21093162
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Prognostic and clinical significance of histone deacetylase 1 expression in breast cancer: A meta-analysis.
    Qiao W; Liu H; Liu R; Liu Q; Zhang T; Guo W; Li P; Deng M
    Clin Chim Acta; 2018 Aug; 483():209-215. PubMed ID: 29738697
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Redefining prognostic factors for breast cancer: YB-1 is a stronger predictor of relapse and disease-specific survival than estrogen receptor or HER-2 across all tumor subtypes.
    Habibi G; Leung S; Law JH; Gelmon K; Masoudi H; Turbin D; Pollak M; Nielsen TO; Huntsman D; Dunn SE
    Breast Cancer Res; 2008; 10(5):R86. PubMed ID: 18925950
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Outcome evaluation in pre-trastuzumab era between different breast cancer phenotypes: a population-based study on Italian women.
    Cortesi L; De Matteis E; Cirilli C; Marcheselli L; Proietto M; Federico M
    Tumori; 2012 Nov; 98(6):743-50. PubMed ID: 23389361
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The prognostic impact of obesity on molecular subtypes of breast cancer in premenopausal women.
    Turkoz FP; Solak M; Petekkaya I; Keskin O; Kertmen N; Sarici F; Arik Z; Babacan T; Ozisik Y; Altundag K
    J BUON; 2013; 18(2):335-41. PubMed ID: 23818343
    [TBL] [Abstract][Full Text] [Related]  

  • 49. TTK is a favorable prognostic biomarker for triple-negative breast cancer survival.
    Xu Q; Xu Y; Pan B; Wu L; Ren X; Zhou Y; Mao F; Lin Y; Guan J; Shen S; Zhang X; Wang C; Zhong Y; Zhou L; Liang Z; Zhao H; Sun Q
    Oncotarget; 2016 Dec; 7(49):81815-81829. PubMed ID: 27833085
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The maximum standardized uptake value of metastatic site in 18 F-FDG PET/CT predicts molecular subtypes and survival in metastatic breast cancer: An Izmir Oncology Group study.
    Cokmert S; Tanriverdi O; Karapolat I; Demir L; Bayoglu V; Can A; Akyol M; Yilmaz Y; Oktay Tarhan M
    J BUON; 2016; 21(6):1410-1418. PubMed ID: 28039701
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Tumor-infiltrating lymphocytes are significantly associated with better overall survival and disease-free survival in triple-negative but not estrogen receptor-positive breast cancers.
    Krishnamurti U; Wetherilt CS; Yang J; Peng L; Li X
    Hum Pathol; 2017 Jun; 64():7-12. PubMed ID: 28153508
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Race and hormone receptor-positive breast cancer outcomes in a randomized chemotherapy trial.
    Sparano JA; Wang M; Zhao F; Stearns V; Martino S; Ligibel JA; Perez EA; Saphner T; Wolff AC; Sledge GW; Wood WC; Davidson NE
    J Natl Cancer Inst; 2012 Mar; 104(5):406-14. PubMed ID: 22250182
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Prognostic significance of SATB1 in gastrointestinal cancer: a meta-analysis and literature review.
    Zhang S; Tong YX; Xu XS; Lin H; Chao TF
    Oncotarget; 2017 Jul; 8(29):48410-48423. PubMed ID: 28430598
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Prognostic significance of p53, angiogenesis, and other conventional features in operable breast cancer: subanalysis in node-positive and node-negative patients.
    Gasparini G; Toi M; Verderio P; Ranieri G; Dante S; Bonoldi E; Boracchi P; Fanelli M; Tominaga T
    Int J Oncol; 1998 May; 12(5):1117-25. PubMed ID: 9538138
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Stratification of Prognosis of Triple-Negative Breast Cancer Patients Using Combinatorial Biomarkers.
    Yue Y; Astvatsaturyan K; Cui X; Zhang X; Fraass B; Bose S
    PLoS One; 2016; 11(3):e0149661. PubMed ID: 26930401
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Expression of p16 and pRB in invasive breast cancer.
    Shin E; Jung WH; Koo JS
    Int J Clin Exp Pathol; 2015; 8(7):8209-17. PubMed ID: 26339389
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Nuclear IRS-1 predicts tamoxifen response in patients with early breast cancer.
    Migliaccio I; Wu MF; Gutierrez C; Malorni L; Mohsin SK; Allred DC; Hilsenbeck SG; Osborne CK; Weiss H; Lee AV
    Breast Cancer Res Treat; 2010 Oct; 123(3):651-60. PubMed ID: 19924529
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Serum Dickkopf-1 expression level positively correlates with a poor prognosis in breast cancer.
    Zhou SJ; Zhuo SR; Yang XQ; Qin CX; Wang ZL
    Diagn Pathol; 2014 Aug; 9():161. PubMed ID: 25116444
    [TBL] [Abstract][Full Text] [Related]  

  • 59. c-erbB-2 and the "triple-state" in early breast carcinomas.
    Sivridis E; Stamos C; Fiska A; Nikolettos N; Koukourakis MI; Giatromanolaki A
    Med Oncol; 2010 Sep; 27(3):578-84. PubMed ID: 19548127
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Comparative prognostic analysis for triple-negative breast cancer with metaplastic and invasive ductal carcinoma.
    Li Y; Zhang N; Zhang H; Yang Q
    J Clin Pathol; 2019 Jun; 72(6):418-424. PubMed ID: 30872384
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.